BioMarin announces the selection of Ian T. Clark for the company's Board of Directors.
Ian T. Clark Joins BioMarin Pharmaceutical's Board of Directors
Ian T. Clark, a seasoned biopharmaceutical executive, has been appointed to the Board of Directors of BioMarin Pharmaceutical Inc., effective August 1, 2025.
Clark brings a wealth of industry experience to BioMarin, having served as CEO of Genentech from 2010 until his retirement in 2016. During his tenure at Genentech, he oversaw the launch of 15 new drugs, demonstrating his ability to drive innovation and product development.
Before his time at Genentech, Clark held senior roles at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals, and G.D. Searle. This extensive industry experience, spanning over two decades, has positioned him to significantly contribute to BioMarin's strategic direction and innovation in drug development.
Clark's board experience is diverse, having served on the boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Avrobio, Inc., and Kite Pharma, Inc., among others. He is also currently an advisor to KKR & Co. Inc.
BioMarin is a global biotechnology company dedicated to translating genetic discoveries into medicines. With a proven track record of innovation, the company currently has eight commercial therapies and a strong clinical and preclinical pipeline.
For media inquiries, please contact Erin Rau at (925) 683-9622. For investor relations, Traci McCarty can be reached at (415) 455-7558.
As BioMarin continues to push the boundaries of scientific discovery, the addition of Clark to their Board of Directors is expected to further strengthen their position in the biotech industry. While specifics on his contributions and impact at BioMarin are not yet publicly available, given his very recent appointment, Clark’s history suggests he will likely influence company strategy through his expertise in product launches, biotech innovation, and corporate governance, helping drive BioMarin’s pipeline development and commercial strategy forward.
[1] BioMarin Press Release, Ian T. Clark Joins BioMarin Pharmaceutical's Board of Directors [2] BioMarin Company Profile, BioMarin Pharmaceutical Inc. [3] Genentech Company Profile, Genentech
The appointment of Ian T. Clark, a seasoned executive with extensive industry experience, to BioMarin Pharmaceutical's Board of Directors opens opportunities for strategic financial planning and industry-leading business decisions in the biotech sector. With his proven track record in launching new drugs and driving innovation in the finance and biotech industries, Clark's contributions are anticipated to significantly affect finance, business, and cloud news related to BioMarin's pipeline development and commercial strategy.
